| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Selahittin Çayan, Ahmet Barış Altay, Amarnath Rambhatla, Giovanni M Colpi, Ashok Agarwa. Is There a Role for Hormonal Therapy in Men with Oligoasthenoteratozoospermia (OAT)? Journal of clinical medicine. vol 14. issue 1. 2025-01-11. PMID:39797269. |
in addition, dopamine agonists may play a role in enhancing spermatogenesis in infertile men with hyperprolactinemia. |
2025-01-11 |
2025-01-14 |
Not clear |
| Lei Yang, Qiuyu Zhang, Chao Li, Hongjun Tian, Chuanjun Zhu. Exploring the potential pharmacological mechanism of aripiprazole against hyperprolactinemia based on network pharmacology and molecular docking. Schizophrenia (Heidelberg, Germany). vol 10. issue 1. 2024-11-07. PMID:39511179. |
aripiprazole's intervention in hyperprolactinemia primarily targets the following core proteins: solute carrier family 6 member 3 (slc6a3), monoamine oxidase (mao-b), dopamine d2 receptor (drd2), 5-hydroxytryptamine (serotonin) receptor 2a (htr2a), 5-hydroxytryptamine (serotonin) receptor 2c (htr2c), cytochrome p450 2d6 (cyp2d6), dopamine d1 receptor (drd1), dopamine d4 receptor (drd4). |
2024-11-07 |
2024-11-16 |
Not clear |
| Laura Dery, Ilan Shimon, Yaron Rudman, Hiba Masri Iraqi, Shiri Kushnir, Tzipora Shochat, Odelia Cooper, Amit Akiro. Breast Cancer risk in patients with dopamine agonist-treated hyperprolactinemia. Journal of endocrinological investigation. 2024-10-30. PMID:39476176. |
breast cancer risk in patients with dopamine agonist-treated hyperprolactinemia. |
2024-10-30 |
2024-11-02 |
Not clear |
| Unai Diaz-Moreno, Cheng Guang Gan, Divya Pujari, Hoong-Wei Gan, Spyros Batzio. L-Dopa Might Be Insufficient to Suppress Development of Prolactinomas in Dihydropteridine Reductase-Deficiency Patients. JCEM case reports. vol 2. issue 10. 2024-09-30. PMID:39346013. |
due to low levels of dopamine, patients present with hyperprolactinemia. |
2024-09-30 |
2024-10-02 |
Not clear |
| Lukas Andereggen, Angelo Tortora, Gerrit A Schubert, Christian Musahl, Janine Frey, Andrea Stieger, Béatrice Kobel, Markus M Luedi, Michel Roethlisberger, Luigi Mariani, Jürgen Beck, Emanuel Chris. Characteristics and outcomes of men with erectile dysfunction as the presenting symptom due to a lactotroph adenoma. Acta neurochirurgica. vol 166. issue 1. 2024-08-01. PMID:39085672. |
both dopamine agonists (das) and transsphenoidal surgery (tss) correct hyperprolactinemia and restore gonadal function. |
2024-08-01 |
2024-08-03 |
Not clear |
| Falaguasta Daniele, Garelli Silvia, Mazzucato Marta, Presotto Fabio, Tresso Silvia, De Riva Carl. Aggressive Prolactinoma with Progression to Pituitary Carcinoma: A Case Report. Endocrine, metabolic & immune disorders drug targets. 2024-07-30. PMID:39075962. |
hormonal tests revealed hyperprolactinemia and panhypopituitarism; he received hormonal replacement and dopamine agonists (da) therapy with a reduction in prolactin levels. |
2024-07-30 |
2024-08-02 |
Not clear |
| Awais Paracha, Umar Durrani, Satvik Vasireddy, Ali Abid, Fatima Waheed, Michael Thomur. Determining Ideal Management for Patients With Coexisting Prolactinomas and Psychiatric Symptoms: A Systematic Review. Journal of psychiatric practice. vol 30. issue 3. 2024-05-31. PMID:38819244. |
psychiatric conditions are often treated with dopamine antagonists, which can induce hyperprolactinemia. |
2024-05-31 |
2024-06-06 |
Not clear |
| Cristina Laguna Benetti-Pinto, Andrea Prestes Nácul, Ana Carolina Japur de Sá Rosa-E-Silva, Gustavo Arantes Rosa Maciel, Vania Dos Santos Nunes Nogueira, Paula Condé Lamparelli Elias, Manoel Martins, Leandro Kasuki, Heraldo Mendes Garmes, Andrea Gleze. Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM). Archives of endocrinology and metabolism. vol 68. 2024-04-05. PMID:38578473. |
dopamine agonists are the first line of treatment for patients with symptomatic hyperprolactinemia due to prolactinomas and in those with idiopathic hyperprolactinemia. |
2024-04-05 |
2024-04-07 |
Not clear |
| Cristina Laguna Benetti-Pinto, Andrea Prestes Nácul, Ana Carolina Japur de Sá Rosa-E-Silva, Gustavo Arantes Rosa Maciel, Vania Dos Santos Nunes Nogueira, Paula Condé Lamparelli Elias, Manoel Martins, Leandro Kasuki, Heraldo Mendes Garmes, Andrea Gleze. Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM). Archives of endocrinology and metabolism. vol 68. 2024-04-05. PMID:38578473. |
infertility treatment of patients with hyperprolactinemia is also carried out with dopamine agonists, aiming for the normalization of prolactin levels. |
2024-04-05 |
2024-04-07 |
Not clear |
| Si-Yu Zhai, Hong-Wei Gu, Cong Wang, Yu-Sang Li, He-Bin Tan. Gynura procumbens and selected metabolites: Amelioration of depressive-like behaviors in mice and risperidone-induced hyperprolactinemia in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 173. 2024-03-01. PMID:38428310. |
in the context of risperidone-induced hyperprolactinemia, eegs lowered blood prolactin levels, reduced the dimensions of rat nipples, and enhanced lh, progesterone, and dopamine levels, alongside mitigating mammary hyperplasia. |
2024-03-01 |
2024-03-04 |
mouse |
| Shereen Khattab, Catherine H Yu, Sapna Sha. Prolactinoma and Adenomyosis - More than Meets the Eye: A Case Report. AACE clinical case reports. vol 10. issue 1. 2024-02-02. PMID:38303768. |
to report a case of adenomyosis in a woman with hyperprolactinemia which resolved after initiation of dopamine agonist therapy. |
2024-02-02 |
2024-02-04 |
Not clear |
| A G Kamaha Tchekep, V Suryanarayanan, Deepak K Pattanaya. New insight into interference-free and highly sensitive dopamine electroanalysis. Analytica chimica acta. vol 1291. 2024-01-27. PMID:38280788. |
early diagnosis of parkinson's disease and hyperprolactinemia based on electrochemical dopamine (da) sensing appears as an efficient and promising practical diagnostic method. |
2024-01-27 |
2024-01-30 |
human |
| Liam J Heneghan, Amanda Tsang, Cara Dimino, Alexander G Khandji, Sunil Kumar Panigrahi, Gabrielle Page-Wilso. Ropinirole for the Treatment of Hyperprolactinemia: A Dose Escalation Study of Efficacy and Tolerability. The Journal of clinical endocrinology and metabolism. 2023-09-16. PMID:37715962. |
treatment of hyperprolactinemia with ergoline dopamine agonists (das) can be complicated by intolerance and resistance. |
2023-09-16 |
2023-10-07 |
Not clear |
| Liam J Heneghan, Amanda Tsang, Cara Dimino, Alexander G Khandji, Sunil Kumar Panigrahi, Gabrielle Page-Wilso. Ropinirole for the Treatment of Hyperprolactinemia: A Dose Escalation Study of Efficacy and Tolerability. The Journal of clinical endocrinology and metabolism. 2023-09-16. PMID:37715962. |
this study examines the efficacy and tolerability of the non-ergot dopamine agonist ropinirole for the long-term treatment of hyperprolactinemia. |
2023-09-16 |
2023-10-07 |
Not clear |
| Yılmaz Yıldız, Oya Kuseyri Hübschmann, Ayça Akgöz Karaosmanoğlu, Filippo Manti, Meryem Karaca, Ida Vanessa D Schwartz, Roser Pons, Eduardo López-Laso, Natalia Alexandra Julia Palacios, Francesco Porta, Ivana Kavecan, Mehmet Cihan Balcı, Marisela E Dy-Hollins, Suet-Na Wong, Mari Oppebøen, Leonardo Simão Medeiros, Leila Cristina Pedroso de Paula, Angeles García-Cazorla, Georg F Hoffmann, Kathrin Jeltsch, Vincenzo Leuzzi, Gülden Gökçay, Daniel Hübschmann, Inga Harting, Z Alev Özön, Serap Sivri, Thomas Oplade. Levodopa-refractory hyperprolactinemia and pituitary findings in inherited disorders of biogenic amine metabolism. Journal of inherited metabolic disease. 2023-07-15. PMID:37452721. |
the potential of slow-release levodopa formulations and low-dose dopamine agonists as part of first-line therapy in prevention and treatment of hyperprolactinemia should be investigated further in animal studies and human trials. |
2023-07-15 |
2023-08-14 |
human |
| Matheo Augusto Morandi Stumpf, Felipe Moura Maia Pinheiro, Gilberto Ochman Silva, Valter Angelo Sperling Cescato, Nina Rosa Castro Musolino, Malebranche Berardo Carneiro Cunha-Neto, Andrea Gleze. How to manage intolerance to dopamine agonist in patients with prolactinoma. Pituitary. 2023-04-07. PMID:37027090. |
dopamine agonists (da) are the gold-standard for prolactinoma and hyperprolactinemia treatment. |
2023-04-07 |
2023-08-14 |
Not clear |
| Amit Akirov, Yaron Rudma. The Role of Aromatase Inhibitors in Male Prolactinoma. Journal of clinical medicine. vol 12. issue 4. 2023-02-25. PMID:36835974. |
dopamine agonists are the recommended treatment for male prolactinomas, but some patients may develop dopamine-agonist-resistant hyperprolactinemia, leading to persistent hypogonadism that requires treatment with testosterone. |
2023-02-25 |
2023-08-14 |
Not clear |
| Yanyang Zeng, Qingliang Huang, Yunzhi Zou, Jiacong Tan, Wu Zhou, Meihua L. The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis. Frontiers in endocrinology. vol 14. 2023-02-10. PMID:36761195. |
three dopamine agonists [bromocriptine, cabergoline, and quinagolide (cv)] have been used for hyperprolactinemia treatment for decades. |
2023-02-10 |
2023-08-14 |
Not clear |
| Mirela E Iancu, Alice I Albu, Dragoș N Alb. Prolactin Relationship with Fertility and In Vitro Fertilization Outcomes-A Review of the Literature. Pharmaceuticals (Basel, Switzerland). vol 16. issue 1. 2023-01-21. PMID:36678618. |
administration of dopamine agonists for hyperprolactinemia preceding ivf treatment does not seem to negatively impact the ivf results, while treatment of transient hyperprolactinemia during ivf might be beneficial in terms of fertilization rates and conception rates. |
2023-01-21 |
2023-08-14 |
Not clear |
| O Y Leshchenk. [Hyperprolactinemia in the postmenopause: versions and contraversions]. Terapevticheskii arkhiv. vol 93. issue 10. 2022-10-26. PMID:36286827. |
treatment with dopamine agonists is usually long-term, the goals of which are to reduce tumor size, normalize prolactin levels and the negative effects of hyperprolactinemia. |
2022-10-26 |
2023-08-14 |
Not clear |